Drugs / penclomedine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00002946 | Oct 1997 → Apr 2002 | lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00002915 | Dec 1996 → ? | cancer of unknown primary site | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | penclomedine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002915 ↗ |
| Known as | NSC-338720 | ChEMBL registry synonym — accepted as the source's own label CHEMBL273124 ↗ |
| Modality | Small molecule | — CHEMBL273124 ↗ |
| Route | Oral | “Patients receive oral penclomedine for 5 consecutive days every 4 weeks.” NCT00002915 ↗ |